Free Trial

NovoCure Q3 2023 Earnings Report

NovoCure logo
$30.51 +0.66 (+2.21%)
(As of 12/3/2024 06:07 PM ET)

NovoCure EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.25

NovoCure Revenue Results

Actual Revenue
$127.30 million
Expected Revenue
$128.75 million
Beat/Miss
Missed by -$1.45 million
YoY Revenue Growth
-2.80%

NovoCure Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

NovoCure Earnings Headlines

NovoCure (NASDAQ:NVCR) Raised to Outperform at Evercore ISI
Even Trump can’t stop what’s coming.
No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.
NovoCure’s PANOVA-3 Trial Success Boosts Oncology Prospects
Wedbush Reiterates Neutral Rating for NovoCure (NASDAQ:NVCR)
See More NovoCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

View NovoCure Profile

More Earnings Resources from MarketBeat